gms | German Medical Science

Deutscher Rheumatologiekongress 2023

51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)
37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)
33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

30.08. - 02.09.2023, Leipzig

Article

Send article

Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero

Meeting Abstract

Search Medline for

  • Monika Østensen - Sørlandets Hospital Kristiansand, Rheumatologie, Kristiansand
  • Helle Bitter - Sørlandet sykehus Kristiansand, Arendal og Flekkefjord, Rheumatology, Kristiansand
  • David Warren - Universitätsklinikum Oslo, Rikshospitalet, Medical Biochemistry, Oslo
  • Nils Bolstad - Sørlandets Hospital Kristiansand, Rheumatologie, Kristiansand
  • Anne Noraas - Spezialistenpraxis, Rheumatologie, Kristiansand

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Leipzig, 30.08.-02.09.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocVS.09

doi: 10.3205/23dgrh240, urn:nbn:de:0183-23dgrh2409

Published: August 30, 2023

© 2023 Østensen et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Introduction: Transplacental passage of BEL has not been studied in humans. We have studied the transfer of BEL as well as B-cell levels in a mother-and-child pair exposed to BEL in pregnancy. A 29-year-old woman with SLE was treated with BEL 10 mg/kg/month in her 2nd pregnancy in addition to prednisone, azathioprine (AZA) and hydroxychloroquine (HCQ). She received the last infusion of BEL at gestational week 26. She experienced no complications during pregnancy and delivered a healthy boy at gestational week 40.

Methods: Blood samples from the mother and the child were taken at delivery and at 4 and 7 months after delivery. CD19+B-cells were measured by flow cytometry. BEL levels were determined using a drug-capture assay [1].

Results: Table 1 [Tab. 1].

Conclusion: B-cell numbers in the child were reduced at birth but were within normal reference values by 4 months post-partum when BEL was undetectable in serum. The child developed normally, had no infection during the first year of life and responded normally to vaccination at 3 and 5 months of age with a high anti-pneumococcus titer at 7 months [2].

Outline

References

1.
Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellström B, Holdaas H, Åsberg A, Bergan S, Vethe NT, Warren DJ. A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. Ther Drug Monit. 2019 Feb;41(1):11-8. DOI: 10.1097/FTD.0000000000000580 External link
2.
Bitter H, Bendvold AN, Østensen ME. Lymphocyte changes and vaccination response in a child exposed to belimumab during pregnancy. Ann Rheum Dis. 2018 Nov;77(11):1692-3. DOI: 10.1136/annrheumdis-2018-213004 External link